Pharmaceutical care of a case of hepatitis B virus reactivation induced by iparomlimab and tuvonralimab
|更新时间:2025-12-26
|
Pharmaceutical care of a case of hepatitis B virus reactivation induced by iparomlimab and tuvonralimab
“In the field of immunotherapy, experts analyzed the cases of hepatitis B virus reactivation caused by epalolito voralimab, revealed the clinical characteristics and potential mechanism of adverse reactions related to inhibitors at immune checkpoints, and provided reference for clinical medication.”
LI Duohui,XU Jingyu,LI Lin,et al.Pharmaceutical care of a case of hepatitis B virus reactivation induced by iparomlimab and tuvonralimab[J].ZHONGGUO YAOFANG,2025,36(24):3113-3117.
LI Duohui,XU Jingyu,LI Lin,et al.Pharmaceutical care of a case of hepatitis B virus reactivation induced by iparomlimab and tuvonralimab[J].ZHONGGUO YAOFANG,2025,36(24):3113-3117. DOI: 10.6039/j.issn.1001-0408.2025.24.17.
Pharmaceutical care of a case of hepatitis B virus reactivation induced by iparomlimab and tuvonralimab